Stephanie S. Okey, M.S.

Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company

Stephanie S. Okey, M.S. has served in various positions of increasing responsibility in the biopharmaceutical industry for over 25 years. She began her career at Bristol Myers Squibb in 1986, then over 7 years at Genentech, Inc., followed by 19 years at Genzyme, A Sanofi Company. Ms. Okey’s management experience during her tenure at Genyzme included serving as Senior Vice President, Head of North America, Rare Diseases, and U.S. General Manager, Rare Diseases from August, 2012 to July, 2015 and as Vice President and General Manager, U.S. Genetic Diseases Business Unit from September, 2011 to August, 2012. She has extensive launch and commercialization experience with nine rare and orphan disease therapeutics; two with REMS designation, and four large market therapeutic agents. Ms. Okey’s specific expertise is in bringing therapeutic agents to health care providers, health care stakeholders and patients in a patient centric business model. Ms. Okey retired from Genzyme, A Sanofi Company, in July, 2015. In addition, she previously served as a member of the Board of the California Life Sciences Association from October, 2014 to January, 2016. Ms. Okey holds a B.S. in Zoology from The Ohio State University and a M.S. in Immunology and Medical Microbiology from Wright State University.

Team members

David Chiswell, Ph.D. – Chairman

Former CEO, Cambridge Antibodies (CAT) and Kymab; Non-Executive Chairman, IGEM Therapeutics; Board Member of Bond 2 Development 2 GP

Anne Klibanski, M.D.

President and CEO, Mass General Brigham; Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

Michael Gutch, Ph.D.

Chief Business Officer and Chief Financial Officer, Entasis Therapeutics

Roger A. Jeffs, Ph.D.

Former President and co-CEO, United Therapeutics

Stephanie S. Okey, M.S.

Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company

Davey S. Scoon

Former CFO, Tom’s of Maine; Board of Trustees, Allianz Global Investors

Ron Cooper

President and Chief Executive Officer